Ascend Laboratories, LLC Dabigatran Etexilate Capsules, 75 mg recall: Failed impurity/degradation specification: an OOS result observed in Related
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability
The hazard: Potency, impurity or stability failure
This is a specification failure: testing showed the product does not match what the label promises.
What the notice says: Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability
Why it matters: The product failed a specification test: it may contain more or less active ingredient than the label states, carry an impurity, or degrade before its expiry date. A sub-potent dose can leave a condition untreated; a super-potent one can cause an overdose.
Symptoms and when to call a doctor
The risk depends entirely on the drug. For a medicine where dose matters closely — a blood thinner, an anti-epileptic, a thyroid or heart medicine, insulin — talk to your prescriber before changing anything. Seek urgent care if you have symptoms that suggest too much drug, or if the condition the medicine controls starts breaking through.
This page is general information, not medical advice. If you feel unwell, a clinician who can see you is the only person able to judge your case.
Recall details
- Recall number
- D-0739-2026
- Published
- August 5, 2026
- Risk level
- Class III
- Status
- Ongoing
- Issued by
- U.S. Food and Drug Administration
- Brand
- Ascend Laboratories, LLC
- Product type
- Prescription & OTC drugs
- Units affected
- 936 cartons x 12 x 3 x 10 (in blister pack)
- Distribution
- Nationwide
- Made in
- United States
- Lot / code info
- Lot: 25141586, Exp. April 30, 2027.
Products covered by this recall
Dabigatran Etexilate Capsules, 75 mg, 30-count (3x10) blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7253-04.
Check your product
The notice names 6 codes you can read straight off the package. Type the one printed on yours and the list below narrows to it.
Lot or batch code
Usually ink-stamped near the seam, the cap or the bottom of the pack.
- 25141586
- Exp. April 30
Best-by / use-by date
Printed beside the lot code, not on the price sticker.
- April 30
NDC number
On the carton and again on the bottle or blister label.
- 0904-7253-04
Package size
Match the net weight or the piece count on the front of the pack.
- 75 mg
- 30 count
Codes are lifted verbatim from the FDA — Drug enforcement notice. A code that is missing here may still be covered — the official notice is the complete list.
What to do about Potency
Ascend Laboratories, LLC — This is a specification failure: testing showed the product does not match what the label promises.
- Check the lot number on your pack against the codes listed above before you do anything else.
- Call your prescriber or pharmacist and ask whether to swap the lot, re-test, or change nothing.
- Keep the carton and the leaflet — the lot number is usually printed only on the outer pack.
- Report any change in how the medicine is working to FDA MedWatch, which is where most of these signals originate.
Refunds and replacements
With medicines, a replacement supply matters more than cash, and that is what pharmacies are set up to provide.
- Ask the dispensing pharmacy for a like-for-like replacement from an unaffected lot. This is the fastest route and usually costs nothing.
- For a mail-order or online pharmacy, use the recall line listed on this page rather than the general support queue.
- If the recall voided a fill you had already paid for, your insurer will normally authorise a replacement ahead of schedule. Quote the recall number.
- If you paid out of pocket, ask for a refund of the co-pay or purchase price and keep the receipt the pharmacy issues.
Company contact: Ascend Laboratories, LLC — 135 Us Highway 202 206 Ste 15, Bedminster, NJ, 07921-2608
The official notice
This page summarises a notice published by U.S. Food and Drug Administration. The agency notice is the authoritative version — read it before you act, and treat it as the final word if anything here looks different.
Open the FDA — Drug enforcement record U.S. Food and Drug Administration recalls
Questions people ask about this recall
Why was Ascend Laboratories, LLC prescription & otc drugs recalled?
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability
How do I know if I have the recalled product?
Match the codes printed on your package against the notice: lot code 25141586, Exp. April 30; best-by date April 30. If the code on your package is not on that list, your unit is outside the recall.
What should I do with it right now?
Check the lot number on your pack against the codes listed above before you do anything else.
Can I get my money back?
Ask the dispensing pharmacy for a like-for-like replacement from an unaffected lot. This is the fastest route and usually costs nothing.
Where was the recalled product sold?
It was distributed nationwide.
Related recalls
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran Etexilate Capsules, 75 mg recall: Failed impurity/degradation specification: an OOS result observed in Related
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran Etexilate Capsules, 150 mg recall: Failed impurity/degradation specification: an OOS result observed in Related
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran etexilate Capsules, 150 mg, 20-count carton recall: Failed Impurities/Degradation Specifications: OOS result was observed during
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II…
-
Class II · 3 months ago
Ascend Laboratories, LLC Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg recall: Failed Dissolution Specifications; Olmesartan Medoxomil content below
Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran etexilate Capsules, 110 mg, 60-count carton recall: Failed Impurities/Degradation Specifications: OOS result was observed during
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II…
-
Class II · 4 months ago
Ascend Laboratories, LLC Minocycline Hydrochloride Extended-Release Tablets, USP recall: Failed Dissolution Specifications: An out-of-specification (OOS) result
Failed Dissolution Specifications: An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysis